Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.
Giammanco, A., Cefalù, A.B., Noto, D., Averna, M. (2020). Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide. CURRENT MEDICINAL CHEMISTRY, 27(23), 3773-3783 [10.2174/0929867326666190121120735].
Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide
Giammanco, AntoninaPrimo
;Cefalù, Angelo B;Noto, Davide;Averna, MaurizioUltimo
2020-01-01
Abstract
Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Therapeutic Options for Homozygous Familial Hypercholesterolemia_correted proof.pdf
Solo gestori archvio
Tipologia:
Pre-print
Dimensione
447.74 kB
Formato
Adobe PDF
|
447.74 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
